

# NLRP3 inflammasome activation by estrogen promotes the progression of human endometrial cancer

This article was published in the following Dove Press journal:  
*OncoTargets and Therapy*

Shuang-Ge Liu<sup>1,\*</sup>  
Xiao-Xiong Wu<sup>2,\*</sup>  
Teng Hua<sup>1,\*</sup>  
Xiao-Yan Xin<sup>1</sup>  
Di-Lu Feng<sup>1</sup>  
Shu-Qi Chi<sup>1</sup>  
Xiao-Xiao Wang<sup>1</sup>  
Hong-Bo Wang<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People's Republic of China; <sup>2</sup>Department of Emergency, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People's Republic of China

\*These authors contributed equally to this work

**Background:** Activation of NLRP3 inflammasome is associated with the development and progression of some types of malignant tumors, but its role in endometrial cancer is unclear. This study aimed to investigate the expression and function of NLRP3 inflammasome in endometrial cancer.

**Materials and methods:** The expression levels of NLRP3, its inflammasome components and estrogen receptor  $\beta$  in endometrial cancer and paired non-tumor tissues were detected. The effects of NLRP3 silencing or overexpression on the proliferation, migration, and invasion of Ishikawa and HEC-1A cells were determined. The impact of NLRP3 silencing on the growth of implanted tumors was determined in vivo. The effects of estrogen on NLRP3 inflammasome activation and Ishikawa cell proliferation were determined.

**Results:** The upregulation of NLRP3, ASC, caspase-1, and IL-1 $\beta$  was associated with the progression of endometrial cancer and poor survival. NLRP3 silencing inhibited the proliferation, migration, and invasion of endometrial cancer cells while NLRP3 overexpression had opposite effects. NLRP3 silencing reduced IL-1 $\beta$  and caspase-1 expression and the growth of implanted endometrial tumors, accompanied by decreased pro-IL-1 $\beta$  maturation. Estrogen enhanced NLRP3, ER $\beta$ , pro-IL-1 $\beta$ , IL-1 $\beta$  expression, and endometrial cancer cell proliferation, which were mitigated by treatment with ER $\beta$  inhibitor but not ER $\alpha$  inhibitor.

**Conclusion:** Our results suggest that estrogen acts through ER $\beta$  to enhance the activation of NLRP3 inflammasome and promote the progression of endometrial cancer. NLRP3 inflammasome may be a new therapeutic target for endometrial cancer.

**Keywords:** NLRP3, endometrial cancer, estrogen, inflammasome, ER $\beta$

## Introduction

Endometrial cancer is the most common gynecological malignancy in the developed countries and its incidence is increasing.<sup>1</sup> Although the pathogenesis of endometrial cancer remains unclear, several risk factors such as late menopause onset, post-menopausal estrogen therapy, obesity, hypertension, and diabetes are associated with the development and progression of endometrial cancer. It is notable that obesity, hypertension, and diabetes are associated with chronic inflammation, which may promote the development and progression of cancer.<sup>2,3</sup> However, how inflammation modulates the development and progression of endometrial cancer has not been clarified.

The inflammasome is a large complex in the innate immune response to pathogen-associated molecular patterns or danger-associated molecular patterns.<sup>4</sup> The nucleotide-binding domain, leucine-rich family (NLR), pyrin-containing 3 (NLRP3)

Correspondence: Hong-Bo Wang  
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, People's Republic of China  
Tel +86 1 592 742 7529  
Fax +86 278 572 6362  
Email hb\_wang1969@sina.com

inflammasome can respond to many stimuli.<sup>5</sup> NLRP3 interacts with the adaptor protein of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) through the pyrin domain and recruits pro-caspase-1, which activates and cleaves pro-IL-1 $\beta$  and pro-IL-18 to promote their maturation.<sup>6,7</sup> Recent studies have suggested that NLRP3 inflammasome has a different role in the development of many types of cancers, such as colorectal cancer, melanoma, breast cancer, gastric cancer, and liver cancer.<sup>8,9</sup> While the activation of NLRP3 inflammasome can inhibit colitis-related colorectal cancer, aberrant activation of NLRP3 inflammasome can promote the development of gastric carcinoma, breast cancer, and lung metastasis.<sup>10</sup> However, the role of NLRP3 inflammasome in human endometrial cancer remains elusive.

In this study, we examined the expression levels of NLRP3 and other inflammasome components in human-paired endometrial cancer and adjacent non-tumor tissues. Furthermore, we examined how altered NLRP3 expression affected the proliferation, invasion, migration, and tumor growth of human endometrial cancer cells. Since estrogen is a risk factor of endometrial cancer, we further investigated whether exogenous estrogen can change NLRP3 expression and NLRP3 inflammasome activation in endometrial cancer cells. Our findings indicated that NLRP3 inflammasome activation was associated with the progression of endometrial cancer, and estrogen enhanced NLRP3 inflammasome activation and the proliferation of endometrial cancer cells through ER $\beta$ .

## Materials and methods

### Patients

A total of 31 patients with endometrial cancer were recruited at the Department of Gynecology at the Union Hospital of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China) from January 2014 to December 2016. Their tissue samples were obtained while they underwent surgery. Individual patients were excluded if they received any hormone therapy, radiotherapy, chemotherapy, or immunotherapy before operation, and had any endocrine disease, immunological disease, or other malignancies. Their endometrial cancer and adjacent non-tumor tissue samples were subjected to liquid nitrogen-frozen and paraffin-embedded for immunohistochemistry and qRT-PCR in the Tumor Tissue Sample Library and the Department of Pathology. All experiments were performed following Medical Ethics

and Human Clinical Trial Committee of Union Hospital and all patients provided written informed consent. The demographic and clinical characteristics of patients are shown in Table 1.

### Immunohistochemistry

NLRP3 and ER $\beta$  expression in human tissue sections were examined by immunohistochemistry.<sup>11</sup> Briefly, the paraffin-embedded endometrial cancer and their adjacent non-tumor tissue sections (4  $\mu$ M) were deparaffinized, rehydrated, treated with 3.0% H<sub>2</sub>O<sub>2</sub> and subjected to antigen retrieval in 10 mM sodium citrate. After blocking with 5% fetal bovine serum (FBS) in TBST for 30 mins, the sections were incubated with rabbit polyclonal anti-NLRP3 (1:300, Proteintech, USA), anti-ER $\beta$  (1:1,000, Proteintech, USA) at 4°C overnight. After being washed, the bound antibodies were detected with horse-radish peroxidase (HRP)-conjugated anti-rabbit IgG and visualized with diaminobenzidine, followed by counterstained with hematoxylin. The staining was evaluated by a semi-quantitative scoring system as described previously.<sup>12</sup> In detail, the staining intensity was graded as: 0, no staining; 1, light yellow; 2, brown; and 3, dark brown. The proportion of cells stained was assessed as: 1, <30% staining; 2, 30–70% staining; and 3, >70% staining. The combined score (the value of staining intensity plus the proportion of stained cells) was

**Table 1** Clinicopathological characteristics of 31 patients with endometrial cancer

Characteristics	No. of patients (%)	Age
Normal	31	44.5 $\pm$ 2.2
Endometrial cancer	31	51.0 $\pm$ 1.7
Figo stage		
I	24	
II–III	4	
IV	0	
Histologic grade		
High	13	
Moderate	11	
Low	7	
Regional lymph nodes		
N0	25	
N1	3	
Distant metastasis		
M0	28	
M1	0	

**Notes:** The lymph node status was unclear in three cases and these three cases were not included for the characterization of FIGO stage, regional lymph node metastasis, and distant metastasis.

assessed as follows: 0, negative staining (–); 1–2, weak or focal (+), 3, moderate staining (++), and  $\geq 4$  strong staining (+++). For correlation analysis, the expression of NLRP3 and ER $\beta$  was judged as negative for (–) and positive for (+), (++), and (+++), and the expression of NLRP3 and ER $\beta$  was judged as low for (+), and high for (++) and (+++).

In addition, the levels of Ki67, VEGF, NLRP3, caspase-1, and IL-1 $\beta$  in the xenograft tumors were determined by immunohistochemistry using antibodies for Ki67 (1:1,000, Santa Cruz, USA), VEGF (1:500, Proteintech, USA), NLRP3 (1:300, Proteintech, USA), caspase-1 (1:800, Proteintech, USA) and IL-1 $\beta$  (1:500, ABclonal, USA).

## Cell culture

Human endometrial carcinoma Ishikawa and HEC-1A cells were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China), and cultured in RPMI-1640 and DMEM/F12 medium supplemented with 10% FBS (Gibco, Auckland, NZ) at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>, respectively. In addition, Ishikawa cells were treated in triplicate with vehicle (control) or ICI182870 (0.1–2.5  $\mu$ M) or PHTPP (0.5 or 5  $\mu$ M, Sigma-Aldrich, USA) for 24 h.

## Cell transfection

Ishikawa and HEC-1A cells were cultured in 24-well plates overnight and transduced with control lentivirus (mock) or shNLRP3-1, shNLRP3-2, or NLRP3 lentivirus (Genechem, China) at a MOI of 20. The cells were treated with puromycin for 5 days to generate Ishikawa/mock, Ishikawa/shNLRP3, Ishikawa/NLRP3, HEC-1A/mock, HEC-1A/shNLRP3, and HEC-1A/NLRP3 cells.

## Quantitative real-time PCR

Total RNA was extracted from endometrial tissue or cells by TRIzol (Invitrogen, USA) and each sample of RNA (2  $\mu$ g) was reversely transcribed into cDNA using the PrimeScript RT kit (TaKaRa, China) according to the manufacturer's instruction. qRT-PCR was performed using the TaKaRa SYBR Green PCR kit in the LightCycler CFX96 (Bio-Rad, USA). The primers were as follows: NLRP3 GCTTGCCGACGATGCCTTC and CTGTCATTGTCCTGGTGTCTTCC; ASC CGTTGAGTGGCTGCTGGATG and CAGGCTGGTGTGAACTG AAGAG; Caspase-1 ACACCGCCAGAGCACAAG and TTTCTTCCACAAATGCCTTCCC; IL-1 $\beta$  TGGC TTATTACAGTGGCAATGAGG and AGTGGTGGT

CGGAGATTCGTAG; IL-18 GAGGCGGGCAGATCA CCAG and CAATCTCGGCTCACCCACAACC. The parameters were: 95°C for 5 mins and then 40 cycles of 95°C for 10 s, 60°C for 20 s, and 72°C for 15 s. The data were normalized to the GAPDH and analyzed by the  $2^{-\Delta\Delta C_t}$  method.

## Western blotting

Endometrial tissues were homogenized and cancer cells were lysed in RIPA buffer. After centrifuged, the concentrations of total proteins were determined by BCA. Individual samples (50  $\mu$ g/lane) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis on 10–12% gels and transferred to polyvinylidene fluoride membranes. The membranes were blocked with 5% dry milk in TBST and incubated with rabbit polyclonal anti-NLRP3, anti-ER $\beta$ , anti-Caspase-1, anti-IL-1 $\beta$ , anti-IL-18 (ABclonal, USA), anti-GAPDH (Santa Cruz, USA) or rabbit monoclonal anti-ER $\alpha$  (Cell Signaling Technology, USA) at 4°C overnight. After being washed, the bound antibodies were detected with HRP-conjugated secondary antibodies and visualized using the enhanced chemiluminescent reagent (Bio-Rad, USA). The relative levels of target to GAPDH expression were determined by densitometric analysis using the ImageJ software.

## Cell viability assay

Cell viability was analyzed using a CCK-8 kit (Google Biological, Wuhan, China), according to the manufacture's instruction. The absorbance at 450 nm in individual wells was measured using the EL800 Universal Microplate Reader (BioTek Instruments, Winooski, VT, USA).

## Transwell migration and invasion assays

Cell migration and invasion were determined by transwell assay. Briefly, cells ( $1 \times 10^6$  cells/well) were cultured in the upper chambers of 24-well transwell plates (8- $\mu$ m pores) in serum-free medium. The bottom chambers were added with 20% FBS and the cells were cultured for 24 hrs. The cells at the surface of the upper chamber membrane were removed using a cotton ball. The cells on the bottom membrane of the upper chambers were fixed in 4% paraformaldehyde and stained with 0.5% crystal violet, and the migrated cells were counted in a blinded manner. For invasion

assay, the upper chambers were precoated with Matrigel (BD Biosciences, San Jose, CA, USA).

### Colony formation assay

The clonogenicity of cells was determined by colony formation assay.<sup>13</sup> Briefly, individual groups of cells (500 cells/well) were cultured in triplicate in six-well plate for 10 days. The formed clones with >50 cells were stained with 0.5% crystal violet and counted under a microscope in a blinded manner.

### Wound healing

Cells were cultured in six-well plates and when the cells reached at 85% of the confluency, the monolayer of cells was wounded using a sterile 100- $\mu$ L pipette tip. The cells were cultured in 2% FBS medium for 24 hrs and then imaged.

### Xenograft model of tumors in mice

The animal experiment protocols were approved by Animal Care and Use Committee of Union Hospital, and all animal operations were performed following NIH Guide for the Care and Use of Laboratory Animals. Female BALB/c nude mice at 4 weeks of age were purchased from Huafukang Biotechnology (Beijing, China) and housed in a specific pathogen-free facility in Experimental Animal Centre of Tongji Medical College with free access to food and water. The mice were randomized and implanted subcutaneously with Ishikawa or Ishikawa/shRNA cells ( $2 \times 10^6$ /mouse, 4 mice per group). The growth of implanted tumors was monitored every 5 days using a caliper up to 40 days after inoculation. The mice were sacrificed and their tumor volumes and weights were measured. The tumor volume was determined by the formula:  $V \text{ (mm}^3\text{)} = \text{Length (mm)} \times \text{Width}^2 \text{ (mm}^2\text{)} \times 0.5236$ .

### Statistical analysis

Data are present as the mean  $\pm$  standard error of mean. Comparison of categorical variables was analyzed by  $\chi^2$  test. Comparison of continuous variables was analyzed by two-tailed Student's *t* test or one-way ANOVA. Comparison of non-normally distributed data was analyzed by nonparametric test of two independent samples. A two-tailed *P*-value of <0.05 was considered statistically significant. All statistical analyses were conducted using SPSS statistical software (SPSS Inc., Chicago, IL, USA), version 17.0.

## Results

### Increased NLRP3 expression in endometrial cancer tissues

To determine the potential role of NLRP3 inflammasome in the development and progression of endometrial cancer, the expression of NLRP3 was examined by immunohistochemistry in 31 cancer and their adjacent non-tumor tissues. NLRP3 was predominantly expressed in the cytoplasm of tissue cells, and NLRP3 staining was stronger in cancer tissues than in non-tumor tissues (Figure 1A). Quantitative PCR and Western blot revealed that NLRP3 mRNA and protein levels were significantly higher in cancer tissues than in non-tumor tissues (Figure 1B and C). Statistical analysis indicated that NLRP3 expression was positively associated with cancer stage, but negatively associated with differentiation grade (Figure 1D and E). Moreover, mRNA levels of ASC, caspase-1, and IL-1 $\beta$ , but not IL-18 were significantly higher in cancer tissues than that in non-tumor tissues (Figure 1F–I). Taken together, these data indicate that upregulated NLRP3 inflammasome is associated with the development and progression of endometrial cancer.


### Altered NLRP3 expression modulates biological behaviors of endometrial cancer cells

Next, Ishikawa and HEC-1A cells were transduced with lentivirus to knockdown or overexpress NLRP3. Knockdown of NLRP3 significantly reduced the proliferation, clonogenicity, invasion, and migration in both Ishikawa and HEC-1A cells (Figure 2A–E). In contrast, NLRP3 overexpression enhanced the proliferation, migration, and invasion in both Ishikawa and HEC-1A cells (Figure 2F–H). Furthermore, NLRP3 overexpression increased caspase-1 activation and the release of IL-1 $\beta$  in endometrial cancer cells (Figure 2F). The proliferation ability was decreased by YVAD-cmk, an inhibitor of caspase-1 (Figure 2I). Collectively, these results indicate that upregulated NLRP3 expression promotes the progression of endometrial cancer.

### Knockdown of NLRP3 inhibits the growth of implanted endometrial tumors in vivo

To further determine oncogenic role of NLRP3 in vivo, BALB/c nude mice were injected subcutaneously with Ishikawa/mock or Ishikawa/shNLRP3. At the end of the






**Figure 1** Upregulated NLRP3 inflammasome activation is associated with the progression of human endometrial cancer. (A–C) The expression NLRP3 in 31 endometrial cancer and paired adjacent non-tumor tissues were examined by immunohistochemistry, quantitative PCR, and Western blot. (D–E) Stratification analysis of the association of NLRP3 expression with cancer stage and grade. (F–I) Quantitative PCR analysis of ASC, caspase-1, IL-1 $\beta$ , and IL-18 mRNA levels in endometrial cancer and adjacent non-tumor endometrial tissues. Data are representative images or expressed as individual values or median  $\pm$  75% percentile (magnification  $\times$ 400). \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001.

experiment, the tumors were dissected (Figure 3A). NLRP3 silencing significantly attenuated the growth of implanted endometrial tumors (Figure 3B). Ishikawa/shNLRP3 tumor weight decreased significantly compared to Ishikawa/mock tumor (Figure 3C). Immunohistochemistry and Western blot analysis showed that NLRP3 silencing reduced Ki67, VEGF, NLRP3, caspase-1, and IL-1 $\beta$  levels in tumor tissues (Figure 3D–F). These results confirm the oncogenic role of NLRP3 in endometrial tumor.

### Estrogen enhances ishikawa cell proliferation by upregulating NLRP3 through ER $\beta$


Excess estrogen stimulation is associated with the development of endometrial carcinoma, but it is unclear whether and how estrogen regulates NLRP3 mediated tumor growth. Thus, we treated Ishikawa cells with

estradiol and found that estradiol not only upregulated ER $\alpha$  and ER $\beta$  expression, but also increased NLRP3 and IL-1 $\beta$  expression in Ishikawa cells (Figure 4A). The enhanced NLRP3 expression by estradiol was demolished by treatment with ER $\beta$  inhibitor PHTPP but not by ER $\alpha$  inhibitor ICI182870 (Figure 4B and C). Immunohistochemistry detected high levels of ER $\beta$  in human endometrial tumors (Figure 4D, Table 2), and ER $\beta$  expression was positively associated with NLRP3 expression (Table 3). In addition, estradiol promoted the proliferation of Ishikawa cells, but NLRP3 silencing dramatically reversed the effects (Figure 4E). Finally, PHTPP treatment inhibited the proliferation of Ishikawa cells, but NLRP3 overexpression dramatically reversed the effects (Figure 4F). Collectively, these results suggest that estrogen enhances the proliferation of endometrial cancer cells by upregulating NLRP3 expression in an ER $\beta$ -dependent manner.



**Figure 2** Altered NLRP3 expression modulated the proliferation, clonogenicity, migration, and invasion in endometrial cancer cells. Ishikawa and HEC-1A cells were transduced with lentivirus for NLRP3 silencing. **(A)** Western blot analysis of relative NLRP3 levels in NLRP3 silence cells. The proliferation **(B)**, clonogenicity **(C)**, invasion **(D)**, and wound healing **(E)** in different groups of cells were determined. Ishikawa and HEC-1A cells were transduced with lentivirus for NLRP3 overexpression. **(F)** Western blot analysis of relative NLRP3 levels in NLRP3 overexpressing cells. The relative levels of NLRP3, IL-1 $\beta$ , and caspase-1 were determined by Western blot. Data are representative images or expressed as mean  $\pm$  SEM of each group from three separate experiments. The proliferation **(F)**, migration (mig, **G**), and invasion (inva, **H**) in different groups of cells were determined. **(I)** Caspase-1 inhibitor YVAD-cmk inhibits the proliferation of endometrial cells. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .

**Abbreviations:** ISK, Ishikawa; Casp-1, Caspase-1.




**Figure 3** NLRP3 silencing suppressed the growth of xenotransplant tumors in nude mice. BALB/c nude mice were implanted subcutaneously with Ishikawa/mock or Ishikawa/shNLRP3 cells into their left upper flank. At the end of the experiment, the mice were sacrificed and tumors were dissected (A). Tumor growth curve was monitored (B). Dissected tumors were weighted (C). The levels of Ki67, VEGF, NLRP3, caspase-1, pro-IL-1 $\beta$ , and IL-1 $\beta$  expression in the tumor tissues were determined by immunohistochemistry (scale bar: 50  $\mu$ m) and Western blot (D–F). Data are representative images or expressed as mean  $\pm$  SEM of each group. \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001.

## Discussion

Inflammation is associated with the development and progression of endometrial cancers.<sup>14</sup> Actually, non-steroidal anti-inflammatory drugs may inhibit the growth of endometrial cancer.<sup>15,16</sup> In this study, we investigated the potential role of NLRP3 inflammasome activation in endometrial cancer. We found that upregulated NLRP3 inflammasome activation, such as NLRP3, ASC, caspase-1, and IL-1 $\beta$ , occurred in endometrial cancer tissues and associated with the progression of endometrial cancer. Our data extend previous

observations that NLRP3 inflammasome activation promotes breast cancer metastasis, cervical cancer, lung cancer, and prostate cancer.<sup>17–20</sup> However, our data are in disagreement with the report that NLRP3 inflammasome activation decreased liver cancer progression.<sup>21</sup> Therefore, the role of NLRP3 inflammasome activation may depend on the tumor origination and stage. The promoting effect of NLRP3 inflammasome activation suggests that NLRP3 inflammasome may be a new valuable therapeutic target for the design of therapies for endometrial cancer.



**Figure 4** Estrogen enhanced NLRP3 inflammasome activation and endometrial cancer cell proliferation in vitro. **(A–C)** Ishikawa cells were treated with estrogen, ICI82870 or PHTPP for 24 hrs and relative levels of NLRP3, ERα, ERβ, IL-1β were determined by Western blot. **(D)** The expression of NLRP3 and ERβ in human endometrial cancer tissues was examined by immunohistochemistry (magnification ×400). **(E)** Estrogen promoted the proliferation of Ishikawa cells and NLRP3 silencing dramatically reversed the effects. **(F)** Blockage of ERβ inhibited the proliferation of Ishikawa cells and NLRP3 overexpression dramatically reversed the effects. Data are representative images or expressed as mean ± SEM of each group. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .

**Table 2** Expression of NLRP3 and ERβ in endometrial cancer tissues

	Negative (%)	Positive (%)	$\chi^2$	P-value
NLRP3				
Normal	79.2 (19/24)	20.8 (5/24)	6.158	0.014
Cancer	45.2 (14/31)	54.8 (17/31)		
ERβ				
Normal	83.3 (20/24)	16.7 (4/24)	6.019	0.011
Cancer	51.6 (16/31)	48.4 (15/31)		

**Table 3** NLRP3 expression is positively associated with ERβ expression

NLRP3	ERβ	
	Low	High
Low	10	4
High	5	12
$\chi^2 = 5.427$ , $P = 0.032$		

It is well known that the activation of NLRP3 inflammasome can promote the maturation of IL-1β and epithelial-mesenchymal transition.<sup>22</sup> In this study, we found that knockdown of NLRP3 expression inhibited the proliferation, migration, and invasion of endometrial cancer cells while NLRP3 overexpression had opposite effects. Furthermore, NLRP3 silencing reduced caspase-1 activation and IL-1β maturation in endometrial cancer cells. The



increased levels of IL-1 $\beta$  may enhance IL-8, IL-6, IL-24, and TNF- $\alpha$  to promote inflammatory cascade and the proliferation and migration of endometrial cancer cells.<sup>23–25</sup> Therefore, our findings may provide new insights into the pathogenesis of endometrial cancer.

Chronic estrogen stimulation is the main risk factor of endometrial cancer.<sup>26</sup> Interestingly, while downregulated ER $\alpha$  expression is associated inversely with the progression of endometrial cancer, upregulated ER $\beta$  expression is detected in the low-differentiated endometrial cancer. In this study, we found that the expression of ER $\beta$  increased in endometrial cancer, and was positively correlated with the expression of NLRP3, similar to that in endometriosis.<sup>27</sup> Our data are not consistent with previous observations that decreased levels of NLRP3 and ER $\beta$  expression were associated with the progression and metastasis of liver cancer, and that estrogen inhibited the expression of ASC, NLRP1b, and NLRP3 in the spinal cord tissues in a rat model of spinal cord injury.<sup>28</sup> Importantly, we found that estrogen enhanced NLRP3 inflammasome activation and promoted the proliferation of endometrial cancer cells via ER $\beta$ . Therefore, the different role of estrogen/ER $\beta$ /NLRP3 inflammasome activation in different pathological conditions may be attributed to estrogen dependence and ER $\beta$  expression.

Our study has some limitations. First, we had a small sample size and short follow-up so we could not conclude the relationship between NLRP3 inflammasome activation and the survival of endometrial cancer patients. Second, the mechanistic interaction between estrogen receptor and NLRP3 should be further investigated.

To the best of our knowledge, this is the first study to demonstrate that upregulated NLRP3 inflammasome activation was associated with the progression of endometrial cancer, and NLRP3 inflammasome activation promoted malignant behaviors of endometrial cancer via ER $\beta$ . NLRP3 inflammasome may be a new therapeutic target for endometrial cancer.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin*. 2017;67(1):7–30. doi:10.3322/caac.21387
- Wallace AE, Gibson DA, Saunders PT, Jabbour HN. Inflammatory events in endometrial adenocarcinoma. *J Endocrinol*. 2010;206(2):141–157. doi:10.1677/JOE-10-0072
- Liu M, Zhang X. An integrated analysis of mRNA-miRNA transcriptome data revealed hub regulatory networks in three genitourinary cancers. *Biocell*. 2017;41(1):19–26.
- Man SM, Kanneganti TD. Regulation of inflammasome activation. *Immunol Rev*. 2015;265(1):6–21. doi:10.1111/imr.12296
- Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. *Nat Rev Immunol*. 2013;13(6):397–411. doi:10.1038/nri3452
- von Moltke J, Ayres JS, Kofoed EM, Chavarria-Smith J, Vance RE. Recognition of bacteria by inflammasomes. *Annu Rev Immunol*. 2013;31:73–106. doi:10.1146/annurev-immunol-032712-095944
- Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. *Nature*. 2012;481(7381):278–286. doi:10.1038/nature10759
- Mearini E, Poli G, Cochetti G, Boni A, Egidi MG, Brancorsini S. Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer. *Oncotargets Ther*. 2017;10:2665–2673. doi:10.2147/OTT.S132680
- Weichand B, Popp R, Dziumbila S, et al. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1 $\beta$ . *J Exp Med*. 2017;214(9):2695–2713. doi:10.1084/jem.20160392
- Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. *Cancer Immunol Res*. 2017;5(2):94–99. doi:10.1158/2326-6066.CIR-16-0269
- Zhang J, Wang L, Qiu M, et al. The protein levels of MCM7 and p63 in evaluating lesion severity of cervical disease. *Int J Gynecol Cancer*. 2013;23(2):318–324. doi:10.1097/IGC.0b013e31827f6f06
- Liu S, Hua T, Xin X, Shi R, Chi S, Wang H. Altered expression of hormone receptor, integrin  $\beta$ 3 and pinopode in the endometrium of luteal phase defect women. *Gynecol Endocrinol*. 2017;33(4):315–319. doi:10.1080/09513590.2016.1259405
- Wei Q, Guo P, Mu K, et al. Estrogen suppresses hepatocellular carcinoma cells through ER $\beta$ -mediated upregulation of the NLRP3 inflammasome. *Lab Invest*. 2015;95(7):804–816. doi:10.1038/labinvest.2015.63
- Ueno T, Yabushita H, Iwasaki K, Wakatsuki A. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer. *Eur J Gynaecol Oncol*. 2018;39(2):199–204.
- Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. *Gynecol Oncol*. 2018;148(1):222–232. doi:10.1016/j.ygyno.2017.10.026
- Verdoordt F, Friis S, Dehlendorf C, Albieri V, Kjaer SK. Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: a systematic review and meta-analysis of observational studies. *Gynecol Oncol*. 2016;140(2):352–358. doi:10.1016/j.ygyno.2015.12.009
- Zhang B, Zhang Y, Zhang X, Lv Y. Suspension state promotes extravasation of breast tumor cells by increasing integrin  $\beta$ 1 expression. *Biocell*. 2018;42(1):17–24. doi:10.32604/biocell.2018.06115
- He A, Shao J, Zhang Y, Lu H, Wu Z, Xu Y. CD200Fc reduces LPS-induced IL-1 $\beta$  activation in human cervical cancer cells by modulating TLR4-NF- $\kappa$ B and NLRP3 inflammasome pathway. *Oncotarget*. 2017;8(20):33214–33224.
- Wang Y, Kong H, Zeng X, et al. Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. *Oncol Rep*. 2016;35(4):2053–2064. doi:10.3892/or.2016.4569
- Dupaul-Chicoine J, Arabzadeh A, Dagenais M, et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. *Immunity*. 2015;43(4):751–763. doi:10.1016/j.immuni.2015.08.013
- Wei Q, Mu K, Li T, et al. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. *Lab Invest*. 2014;94(1):52–62. doi:10.1038/labinvest.2013.126
- Wang H, Wang Y, Du Q, et al. Inflammasome-independent NLRP3 is required for epithelial-mesenchymal transition in colon cancer cells. *Exp Cell Res*. 2016;342(2):184–192. doi:10.1016/j.yexcr.2016.02.010
- Berry KK, Varney ML, Dave BJ, Bucana CD, Fidler IJ, Singh RK. Expression of interleukin-8 in human metastatic endometrial carcinoma cells and its regulation by inflammatory cytokines. *Int J Gynecol Cancer*. 2001;11(1):54–60. doi:10.1046/j.1525-1438.2001.011001054.x

24. Oh K, Lee OY, Park Y, Seo MW, Lee DS. IL-1 $\beta$  induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. *BMC Cancer*. 2016;16(1):724. doi:10.1186/s12885-016-2746-7
25. Someya A, Ikegami T, Sakamoto K, Nagaoka I, Esteban FJ. Glucosamine downregulates the IL-1 $\beta$ -induced expression of proinflammatory cytokine genes in human synovial MH7A cells by O-GlcNAc modification-dependent and -independent mechanisms. *PLoS One*. 2016;11(10):e0165158. doi:10.1371/journal.pone.0165158
26. Haring J, Skrzypczak M, Stegerer A, et al. Estrogen receptor  $\beta$  transcript variants associate with oncogene expression in endometrial cancer. *Int J Mol Med*. 2012;29(6):1127–1136.
27. Han SJ, Jung SY, Wu SP, et al. Estrogen receptor  $\beta$  modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis. *Cell*. 2015;163(4):960–974. doi:10.1016/j.cell.2015.10.034
28. Zendedel A, Mönnink F, Hassanzadeh G, et al. Estrogen attenuates local inflammasome expression and activation after spinal cord injury. *Mol Neurobiol*. 2018;55(2):1364–1375. doi:10.1007/s12035-017-0400-2

## OncoTargets and Therapy

Dovepress

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>